Erectile dysfunction (ED) is a common disorder characterized by multifactorial etiology. Cardiovascular disease, diabetes, hormone alterations, and surgical manipulation represent the common causes of ED.
1 Age is also an independent risk factor for ED, with an estimated increase in ED of 4.6% per year between the ages of 60 and 69 years. 2 The introduction of phosphodiesterase-5 inhibitors (PDE5I), like Viagra, in the market has exponentially improved the therapeutic armamentarium for ED. 3 However, the demand for alternative pharmacotherapeutic options continues to growth as a consequence of the increased percentage of the elderly in the society and increasing acknowledgment that a nearly one-third of ED patients do not respond to PDE5I treatment.
Age-related ED is characterized histologically by the loss of the corpus cavernosum smooth muscle tissue and by its substitution with fibrosis. 4 Fibrosis is defined by the excessive accumulation of extracellular connective tissues such as collagen, elastin, and fibronectin. 5 Progressive cavernous fibrosis can provoke mechanical alterations of the penis, reducing its elasticity and compliance, and it can lead at the end to an irreversible ED. 4 Reduction of testosterone levels and NO production and an increased concentration of reactive oxygen species in the penis seem to be responsible for the association between aging and ED. 6 However, recently, research has demonstrated the importance of Rho-associated protein kinase (ROCK) signaling in maintaining a flaccid penile state, and inhibition of ROCK signaling potentiates smooth-muscle relaxation. In aged animals, RhoA pathway inhibition via cavernosal injection of Y-27632 decreases ROCK activity and improves erectile function. 7 More important, several studies have suggested the ROCK participation in the pathogenesis of a broad array of fibrotic diseases. 5 In Asian Journal of Andrology, Cui et al. 8 explored the efficacy and the underlying mechanisms of human Tissue kallikrein 1 (hKLK1) on age-related corpora fibrosis using a rat model of the disease. Tissue kallikrein 1 (KLK1), a member of the serine proteinase superfamily, is responsible for the production of several kinin peptides. Recent studies demonstrated that kallikrein-kinin system (KKS) could be a therapeutic target for cardiovascular diseases and that KLK gene delivery could reduce renal fibrosis, and the transgenic expression of hKLK1 counteracts the progression of cardiac fibrosis in a rat model of diabetic cardiomyopathy. 8, 9 In the present study, 8 male wild-type Sprague-Dawley rats (WTR) and transgenic rats harboring the hKLK1 gene (TGR) were fed to 4 and 18 months of age, respectively, and divided into three groups: young WTR (yWTR) as the control, aged WTR (18 months, aWTR), and aged TGR (18 months, aTGR). The authors showed that aTGR rats have a better erectile function, less cavernous fibrosis and ROCK system activation than aWTR.
The results of the study are intriguing in that they suggest that hKLK1 might be a new treatment method for age-related ED in
